Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dacarbazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,530Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
    Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris

    13 Dec 2022

    // Kate Goodwin BIOSPACE

    https://www.biospace.com/article/seagen-eyes-a-key-frontline-indication-for-adcetris/

    Kate Goodwin BIOSPACE
    13 Dec 2022
    Share Share
    Teva's troubled plant seen to create injectable drug shortages
    Teva's troubled plant seen to create injectable drug shortages

    24 May 2022

    // Joseph Keenan FIERCEPHARMA

    https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables

    Joseph Keenan FIERCEPHARMA
    24 May 2022
    Share Share
    ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma
    ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma

    03 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220203005330/en

    BUSINESSWIRE
    03 Feb 2022
    Share Share
    Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS
    Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS

    12 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211212005054/en

    BUSINESSWIRE
    12 Dec 2021
    Share Share
    Enforcement Report - Week of March 3, 2021
    Enforcement Report - Week of March 3, 2021

    03 Mar 2021

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-3-2021-1614760051.pdf

    FDA
    03 Mar 2021
    Share Share
    European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD
    European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD

    11 Feb 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190211005381/en/European-Commission-Approves-ADCETRIS%C2%AE-brentuximab-vedotin-AVD

    BUSINESSWIRE
    11 Feb 2019
    Share Share